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Diabetes mellitus (DM) is a common endocrine disease 
in domesticated cats, with a prevalence of approximately 
0.5% in studied populations.1,2 Most cases of feline DM 
closely resemble human type 2 DM, which is character-
ised by a decreased insulin sensitivity in peripheral 
tissues in combination with an inadequate insulin pro-
duction in the pancreatic islets (due to beta-cell failure).3 
Clinical symptoms of DM become evident when insulin 
secretion is no longer able to compensate for the 
increased insulin requirement.4
Lente insulin (Caninsulin; Intervet) has been widely 
used to treat feline diabetes. The duration of effect in cats 
is approximately 8 h (8–14 h), which necessitates at least 
twice-daily administration to achieve acceptable glycae-
mic control.5–7 Even with this protocol, many cats will 
experience periods of hyperglycaemia during the day, 
leading to an increased risk of glucose toxicity and dis-
ease progression.6,8 Therefore, lente insulin may be sub-
optimal for the treatment of certain diabetic cats, and 
assessment of other types of insulin is reasonable.
In recent years, long-acting human insulin analogues 
(eg, glargine [Lantus; Sanofi Aventis] and detemir 
[levemir; Novo Nordisk]) have been used to treat feline 
diabetes. Glargine has a significantly longer duration in 
cats than lente insulin and has provided encouraging 
results in the treatment of feline DM.5,9 Glargine, in com-
bination with a high-protein, low-carbohydrate diet, has 
resulted in higher diabetic remission rates than previ-
ously reported for other types of insulin.9–11 To achieve 
maximum glycaemic control and to increase the chance 
of remission, administration of glargine twice daily is 
recommended.10,12
In humans, detemir is slowly absorbed from the sub-
cutaneous injection site and displays a prolonged action 
compared with other types of insulin.13 Formation of 
dihexamers and the binding of detemir to albumin 
are believed to be the mechanisms behind the slow 
Insulin detemir treatment in  
diabetic cats in a practice setting
Kirsten Madsen Hoelmkjaer, Eva-Maria Hohneck Spodsberg  
and Charlotte Reinhard Bjornvad
Abstract
Insulin detemir is a long-acting insulin analogue and may represent a valuable treatment option for diabetic cats. 
So far, only one study addressing detemir treatment of diabetic cats has been published, and this was based on an 
intensive blood glucose monitoring protocol. The aim of the current, retrospective study was to evaluate the effect 
of detemir therapy in diabetic cats in a general clinical setting. Fourteen diabetic cats with a follow-up period of at 
least 3 months were included. Data were collected from medical records at the University Hospital for Companion 
Animals, University of Copenhagen, Denmark. Thirteen of 14 cats achieved moderate or excellent control of clinical 
symptoms within the initial 3 months of detemir therapy, including five cats previously treated unsuccessfully with 
other types of insulin. Clinical improvements were noted after 1 month of therapy and continued over time. Three 
cats achieved remission within the initial 3 months and none experienced a diabetic relapse during the study 
period. One cat achieved remission after 13 months of therapy. Improvements in clinical symptoms were markedly 
better than indicated by blood glucose and serum fructosamine concentrations. The safety of detemir was very 
high, with only two reported episodes of clinical hypoglycaemia, neither of which required veterinary attention. 
Based on these results detemir can be recommended for the treatment of diabetic cats, including cats previously 
treated unsuccessfully with other types of insulin.
Accepted: 14 May 2014
University of Copenhagen, Frederiksberg, Denmark
Corresponding author:
Kirsten Madsen Hoelmkjaer DVM, University of Copenhagen, 
Dyrlaegevej 16, Frederiksberg 1870, Denmark 
Email: holmkjar@sund.ku.dk
538642 JFM0010.1177/1098612X14538642Journal of Feline Medicine and SurgeryHoelmkjaer et al
research-article2014
Original Article
 at Copenhagen University Library on August 18, 2014jfm.sagepub.comDownloaded from 
2 Journal of Feline Medicine and Surgery 
absorption of detemir.13,14 These features could be rele-
vant for use in the treatment of feline DM. So far, detemir 
has only been the subject of a limited number of feline 
studies.15,16 In healthy cats, the pharmacodynamics of 
detemir and glargine were comparable.16 The only pub-
lished study involving diabetic cats reported a high 
remission rate within the first 5 months of treatment 
with detemir, and only 1/18 cats experienced mild hypo-
glycaemia.15 However, this study involved a protocol 
aimed at intensive blood glucose (BG) monitoring, with 
multiple (3–7) daily BG measurements at home; there-
fore, it may not be representative of the standard capa-
bility of owners of feline diabetic patients.15 The objective 
of this study was to report the treatment outcome in a 
group of diabetic cats treated with a protocol based on 
the guidelines from the American Animal Hospital 
Association (AAHA).17 We believe that this study may 
provide a more realistic reflection of the results to be 
expected when using detemir in a general veterinary 
practice setting.
Materials and methods
Medical records for cats diagnosed with DM at the 
University Hospital for Companion Animals (UHC), 
University of Copenhagen, Denmark, between January 
2007 and May 2013 were reviewed. Diagnosis of DM was 
based on clinical symptoms, including polyuria and 
polydipsia, and the combined results of blood and urine 
samples (hyperglyacaemia, increased serum fructosa-
mine and glycosuria). The following were required for 
inclusion: (i) at least 3 months of follow-up from initial 
diagnosis; (ii) a minimum of three hospital visits (initial 
visit followed by a minimum of two follow-up visits) 
and/or three serial BG measurements during the first 3 
months of detemir therapy. Cats were included if they 
had been treated consecutively with detemir for 3 
months, regardless of any previous therapy with another 
type of insulin. The cut-off for data collection was June 
2013, regardless of disease status at that time.
The following data were collected from the medical 
records: signalment, history and physical examination 
findings, as well as the results of complete blood counts, 
biochemical profiles and urinalysis from each visit. 
Information regarding cause of death and occurrence/
duration of remission was also collected when applica-
ble. Diabetic remission was defined as at least 4 weeks of 
glycaemic control without exogenous insulin therapy.18 
Where available, data from home monitoring (eg, BG 
curves [BGCs]) were also included.
The applied treatment protocol for detemir was in 
agreement with the AAHA diabetes management guide-
lines for treatment with insulin glargine and based on 
recommendations by Rucinsky et  al and Rand and 
Marshall.17,19 The starting dose of detemir was based on 
BG concentration: an initial dose of 0.5 U/kg twice daily 
if the BG was >20 mmol/l (360 mg/dl) and 0.25 U/kg 
twice daily if the BG was <20 mmol/l (360 mg/dl). This 
protocol was also applied to cats previously treated with 
other types of insulin, as there can be individual varia-
tions in the time–action profile of detemir, and it was 
unknown how the cats would react to the change in 
insulin type.16 For all cats, the dose was further adjusted 
based on preinsulin BG, BG nadir during a 12 h serial 
BGC and the clinical symptoms. BGCs were generated at 
home or in the hospital using a portable glucometer 
(Contour; Bayer). Several handheld glucometers have 
been shown to provide clinically acceptable readings.20 
During the 12 h BGC the BG was measured every 4 h 
from immediately before the morning insulin injection 
and ending just before the evening dose of insulin.17 A 
mean BG (MBG) was calculated for each BGC as the 
average of the four measurements. During the first week 
of treatment no dose adjustments were made unless 
hypoglycaemic episodes were confirmed or suspected. 
Conducting a 12 h serial BGC was recommended at 
home or in the hospital every 10–14 days until accepta-
ble glucose control was achieved. A preinsulin BG 
between 10 and 15 mmol/l (180–270 mg/dl), and a nadir 
between 5 and 10 mmol/l (90–162 mg/dl) were consid-
ered to show an appropriate level of glycaemic 
control.17,19 
Glycaemic control was also assessed based on clinical 
symptoms and serum fructosamine level. Normalisation 
of clinical symptoms was considered excellent control, 
moderate control was the improvement of clinical symp-
toms without resolution (eg, still some degree of poly-
dipsia and polyuria) and poor control was lack of 
improvement in clinical symptoms.21 Excellent and 
moderate glycaemic control were expected to be associ-
ated with a serum fructosamine level of <450 µmol/l or 
<550 µmol/l, respectively.22 Dose adjustments were 
kept in the range of 0.5–1.0 U/injection. In the case of 
clinical hypoglycaemia, the dose was reduced by 50%.
Owners were encouraged to feed a high-protein, 
low-carbohydrate diabetes diet as an integral part of 
the treatment plan unless a renal diet was indicated by 
concurrent kidney disease.17 Cats were fed at the time 
of insulin administration or had unlimited access to 
food. The necessity of maintaining an optimal body 
condition was emphasised and weight loss, if required, 
was encouraged.
Statistical analysis
Quantitative descriptive data are presented as the 
median and range. Measurements of serum fructosa-
mine concentration, preinsulin BG and nadir BG from 
each cat were divided into three categories based on time 
of measurement from initiation of detemir treatment: 
baseline; day 25–60; and day 61–105. To evaluate any 
change in these measurements over time, the time 
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categories were compared using the Wilcoxon matched 
pairs signed rank sum test. The Kruskal–Wallis test was 
used for comparison of unpaired measurements such as 
starting dose of insulin. Differences were considered sig-
nificant at values of P ⩽0.05. Data are illustrated with 




Thirty diabetic cats treated with detemir were identified 
from the medical records from the UHC. Of these, 14 cats 
fulfilled the inclusion criteria and were included in the 
study. 16 cats were excluded: 4 owing to euthanasia 
within the initial 3 months, 7 were lost to follow-up 
within the initial 3 months and 5 had incomplete follow-
up data; three of the four cats were euthanased within 12 
days of diagnosis (owing to owners’ wishes or concur-
rent disease), and one cat was diagnosed with acute pan-
creatitis/cholangitis and renal failure 60 days after 
receiving a diagnosis of DM. The remaining five cats had 
incomplete follow-up data.
Eleven of the 14 included cats were domestic short-
hairs. The other cats were Maine Coon (n = 1), Somali 
(n = 1) and Norwegian Forest (n = 1). Twelve cats were 
males (two intact and 10 neutered) and two cats were 
neutered females. The median age at time of initiation of 
detemir treatment was 11.0 years (range 3.5–16.9 years). 
The median total hospital follow-up time was 13.4 
months (range 3.0–56.0 months).
Cats given prior insulin treatment
Five cats had been treated with another type of insulin 
prior to treatment with detemir. Four cats had been 
treated with lente insulin (Caninsulin; MSD) for a period 
of between 3 weeks and 3 months. For one cat the type 
and duration of prior insulin therapy was unknown. All 
five cats were second opinion cases owing to persistent 
polyuria/polydipsia (n = 4), lethargy (n = 2), weight loss 
(n = 1), polyphagia (n = 1), anorexia (n = 1), vomiting and 
diarrhoea (n = 1) and hind limb weakness (n = 1). 
Following change to detemir, all five cats showed clinical 
improvements within the first 3 months and achieved 
either moderate or excellent clinical control of their DM. 
One cat achieved remission within 3 months of detemir 
treatment.
Newly diagnosed cats
Two of the nine newly diagnosed cats were diagnosed 
with DM during routine laboratory work for other indi-
cations (screening for feline heart disease and a pre-
anaesthetic senior profile prior to dental treatment) and 
the owners had not noticed any clinical signs of DM. The 
remaining seven cats had clinical symptoms prior to the 
diagnosis of DM: polyuria/polydipsia (n = 7), weight 
loss (n = 3), polyphagia (n = 3), lethargy (n = 2), dry fur 
and scaling fur scale (n = 1), and anorexia (n = 1).
Within the initial 3 months of detemir therapy, 7/9 
cats no longer showed any clinical symptoms of DM 
according to the owners. Improvements were noted after 
approximately 1 month of therapy, and continued to 
improve for the following 2 months. The clinical condi-
tion of one cat had improved, with milder signs of poly-
uria, polydipsia and polyphagia, while the clinical 
condition of one cat did not change despite insulin treat-
ment. Two cats achieved remission within the first 3 
months of detemir therapy.
Diabetic remission
A total of three cats achieved remission during the first 3 
months of detemir therapy. One had been treated with 
lente insulin for 3 weeks before detemir therapy was 
started, while the other two cats were newly diagnosed. 
The time to achieving remission in these cats was 
approximately 70, 30 and 40, days respectively. At the 
end of the study, all three cats had been euthanased for 
reasons other than DM (chronic kidney disease [CKD] 
n = 2, feline asthmatic bronchitis n = 1). Remission had 
lasted for 47, 30 and 15 months, respectively, without 
diabetic relapse.
Eleven cats did not achieve remission in the first 3 
months of detemir therapy. However, one of the 11 cats 
achieved remission after 13 months of therapy. At the 
end of the study, remission had lasted for 4 months in 
this cat with no relapse.
The median starting dose of detemir was 0.3 U/kg 
twice daily in cats achieving remission within 3 months 
and 0.38 U/kg twice daily in cats not achieving early 
remission (P = 0.64).
Cats not in remission at time of data collection
At the end of the study, three cats were still alive, dia-
betic and receiving treatment with detemir. They had 
been treated for a median of 16 months (range 3–56 
months), with two cats having achieved excellent control 
of their disease, while one cat had moderate control of 
disease. Five cats had been euthanased without achiev-
ing remission. For one cat, the date and cause of death 
could not be determined. The remaining four cats had 
been treated with detemir for 9.0, 9.5, 15.1 and 21.5 
months, respectively. The causes of euthanasia were 
insufficient control of DM (n = 2), hepatic neoplasia 
(n = 1) and acute pancreatitis/CKD (n = 1). Two cats 
were lost to follow-up.
Fructosamine concentrations in all cats
The fructosamine levels were measured at the time of 
initiation of detemir treatment in 12 cats. All 12 cats had 
elevated serum fructosamine levels; the median fruc-
tosamine level was 685 µmol/l (range 577–1090 µmol/l, 
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reference range 221–341 µmol/l). For 10 cats, repeated 
measurements of serum fructosamine levels during the 
first 3 months of detemir therapy were available 
(Figure 1). The serum fructosamine concentration was 
significantly reduced 25–60 days (P = 0.047) and 61–105 
days (P = 0.031) after the initiation of detemir treatment. 
There was no significant difference in fructosamine con-
centration at 61–105 days compared with after 25–60 
days (P = 0.25) of detemir treatment. Three cats had at 
least one fructosamine measurement <450 µmol/l 
(Table 1). In 7/10 cats the fructosamine levels did not 
fall below 450 µmol/l, with five cats consistently having 
a fructosamine level >600 µmol/l. The level of clinical 
control in these five cats was excellent (n = 3), moderate 
(n = 1) and poor (n = 1).
BGCs in all cats
Thirteen cats had at least two BGCs performed in the 
first 3 months of detemir therapy. In one cat a complete 
BGC had not been performed, but preinsulin BG was 
monitored sporadically at home. This was one of the 
three cats achieving early remission.
The measurements of preinsulin BG and nadir BG for 
each cat over time are shown in Figures 2 and 3. The pre-
insulin BG decreased in 6/9 cats after 61–105 days com-
pared with after 25–60 days of detemir treatment, but the 
difference was not statistically significant (P = 0.30). In 
the same period of time, the nadir BG decreased in 7/10 
cats (P = 0.32).
Seven cats reached an MBG between 5 and 10 mmol/l 
(90–180 mg/dl), three cats between 10 and 15 mmol/l 
(180–270 mg/dl) and three cats consistently had an MBG 
>15 mmol/l (270 mg/dl). Nine cats achieved a BG nadir 
of <10 mmol/l, three cats between 10–15 mmol/l and 
one cat never had a nadir of <15 mmol/l. Nine cats 
achieved a preinsulin BG of <10 mmol/l, three cats of 
10–15 mmol/l and for one cat the preinsulin BG never 
fell below 15 mmol/l.
Hypoglycaemia
Two out of 14 cats experienced a single episode with clin-
ical symptoms of hypoglycaemia (muscle twitches, leth-
argy and/or weakness). None of the cats required 
hospitalisation or veterinary attention during the epi-
sode, and both cats were taken care of at home by their 
owners. The incidents occurred at detemir doses of 0.5 
U/kg and 0.4 U/kg twice daily, respectively. Further, 
two medical records reported episodes of hypoglycae-
mia (both with a BG of 2.5 mmol/l) during the BGC. 
Those cats did not show any clinical symptoms. The BG 
of both cats was measured at home by the owner using a 
handheld glucometer (Contour; Bayer). The detemir 
doses at the time were approximately 0.5 U/kg and 1 U/
kg twice daily, respectively.
Diet
Six cats were fed a high-protein, low-carbohydrate diet 
(m/d Feline dry; Hill’s Prescription Diet or Diabetic DS 
Figure 1 Mean serum fructosamine concentration in nine 
diabetic cats following initiation of detemir treatment. Time 0 
is initiation of treatment, time 1 is 25–60 days and time 2 is 
61–105 days after the initiation of treatment with detemir.  
P <0.05 between time 0 and 1. P = 0.03 between time 0 and 2
Figure 2 Mean preinsulin blood glucose (BG) concentration 
during a 12 h BG curve in nine diabetic cats following 
initiation of detemir treatment. Time 1 is 25–60 days and time 2 
is 61–105 days after the initiation of treatment with detemir.  
P = 0.30 between time 1 and 2
Figure 3 Mean nadir blood glucose (BG) concentration 
during a 12 h BG curve in 10 diabetic cats following initiation 
of detemir treatment. Time 1 is 25–60 days and time 2 is 
61–105 days after the initiation of treatment with detemir.  
P = 0.32 between time 1 and 2
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45; Royal Canin Veterinary Diets) during the follow-up 
period. The remaining eight cats were fed a combination 
of a high-fibre (w/d Feline dry; Hill’s Prescription Diet) 
and high-protein, low-carbohydrate diet (n = 1), a renal 
diet (n = 2) or an unknown diet (n = 5). The three cats 
achieving early remission were fed a renal diet 
(n = 2) and a high-protein, low-carbohydrate diet (n = 1).
Discussion
Detemir is a long-acting insulin analogue with a phar-
macokinetic profile that may render it suitable for treat-
ment of diabetic cats. A previous report indicated a high 
rate of diabetic remission and a good safety profile of 
detemir in diabetic cats.15 However, the study involved a 
very intensive monitoring protocol. In the current study, 
the effect of detemir was evaluated in a setting more 
closely resembling a general veterinary practice situa-
tion. The majority of our diabetic cat population was 
neutered males, consistent with previous studies.23 The 
median age and presenting symptoms in the cats newly 
diagnosed with DM were also consistent with previous 
reports.23,24
A minimum follow-up period of 3 months was used 
as an inclusion criterion based on previous studies show-
ing that clinical symptoms improved in diabetic cats 
treated with other types of insulin within this time-
frame.21,25,26 Thus, in a study with protamine zinc insu-
lin, 90% of owners reported improvement or resolution 
of clinical signs by day 45 of treatment.25 With lente 
insulin the clinical signs were significantly resolved 
within 3 months.26 In the current study, the clinical 
symptoms were improved after 1 month of detemir 
treatment in 13/14 cats and continued to improve dur-
ing the following 2 months. Therefore, when using a pro-
tocol based on AAHA recommendations, detemir does 
not apparently lead to a faster control of clinical symp-
toms compared with other types of insulin. However, 
further studies with more stringent timing of follow-up 
visits are needed in order to fully evaluate this.
The majority of cats in our study achieved moderate 
or excellent control of clinical signs within the initial 3 
months of detemir therapy, regardless of the duration of 
their disease and possible previous treatment with other 
types of insulin. Hence, detemir appears to be equally 
able to improve the clinical symptoms compared with 
other types of insulin.25–27 Furthermore, five cats previ-
ously treated unsuccessfully with other types of insulin 
all achieved either moderate or excellent control follow-
ing a change to detemir. Four of the five cats were ini-
tially treated with lente insulin, which has too short a 
duration of effect for twice-daily dosing in some cats.5,7 
Because no BGCs were available from the prior treat-
ment period, no conclusions could be made about the 
cause for the initial unsuccessful insulin treatment in 
those cats.
According to previous reports, the chance of remis-
sion is greatest during the initial 2–4 months of insulin 
therapy.9,28,29 In the current study, 21% of the cats 
Table 1 Assessment of glycaemic control based on serum fructosamine concentration, mean blood glucose (MBG) and 
nadir during a 12 h blood glucose (BG) curve, and owner observations in 14 cats treated with detemir for 3 months
All cats Previously treated Newly diagnosed  
Glycaemic control Total (n) Total (n) Total (n)
Good control based on:  
Fructosamine (<450 µmol/l)  3 (30%) 10 1 (33%) 3 2 (29%) 7
MBG (<10 mmol/l)*  7 (54%) 13 2 (50%) 4 5 (56%) 9
Nadir (<10 mmol/l)  9 (69%) 13 3 (33%) 4 6 (67%) 9
Owner observations 10 (71%) 14 3 (60%) 5 7 (78%) 9
  
Moderate control based on:  
Fructosamine (450–550 µmol/l)  0 (0%) 10 0 (0%) 3 0 (0%) 7
MBG (10–15 mmol/l)  3 (23%) 13 1 (25%) 4 2 (22%) 9
Nadir (10–15 mmol/l)  3 (23%) 13 1 (25%) 4 2 (22%) 9
Owner observations  3 (21%) 14 2 (40%) 5 1 (11%) 9
  
Poor control based on:  
Fructosamine (>550 µmol/l)  7 (70%) 10 2 (66%) 3 5 (71%) 7
MBG (>15 mmol/l)  3 (23%) 13 1 (25%) 4 2 (22%) 9
Nadir (>15 mmol/l)  1 (7%) 13 0 (0%) 4 1 (11%) 9
Owner observations†  1 (7%) 14 0 (0%) 5 1 (11%) 9
* MBG is the mean value of BG concentration measured every 4 h for 12 h
† Owner observations: good control is normalisation of clinical symptoms, moderate control is improvement of clinical symptoms without 
resolution (eg, still some increased thirst and urination) and poor control is lack of improvement in clinical symptoms
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achieved remission within this timeframe, which is con-
siderably lower than previously reported for detemir, 
where 67% of treated cats achieved remission.15 However, 
some of these cats achieved remission after more than 
3 months of therapy, and this makes a direct comparison 
difficult. Still, the median time to achieving remission 
was comparable in the two studies (1.3 versus 1.7 
months) and also comparable with previous reports 
with various types of insulin.10,26,27,30
The previous study with detemir involved a very 
tight monitoring protocol with between three and seven 
daily measurements of BG, which was far more rigorous 
than recommended by the AAHA and the protocol 
applied in our study.17 This highlights the importance of 
fastidious monitoring, as it might improve the chance of 
remission, which is consistent with the results of previ-
ous studies.9,28,29 However, we believe that the results 
from our study may be a more realistic representation of 
the chance of remission to be expected in a general vet-
erinary practice using detemir. Previous retrospective 
reports have found a remission rate comparable with 
ours (16.7% gained remission after a median time of 6 
months) in cats treated with various types of insulin.21
Initially, all cats presented with an elevated serum 
fructosamine level, which decreased significantly over 
time. Based on this parameter alone, only 3/10 cats in 
our study had excellent glycaemic control (fructosamine 
<450 µmol/l) and none had moderate glycaemic control 
(fructosamine <550 µmol/l).22 However, the majority of 
the cats had excellent or moderate glycaemic control 
based on their clinical symptoms (Table 1). These find-
ings are consistent with previous reports, indicating that 
fructosamine alone is suboptimal for evaluating diabetic 
control in cats, and should be combined with other 
parameters such as clinical symptoms.31–33
Most owners were able to perform BG measurements 
at home using a portable glucometer. Despite improve-
ment in clinical symptoms, the preinsulin BG and nadir 
BG was only moderately decreased after 105 days of 
treatment. This may reflect that calculations were based 
on the mean preinsulin BG and mean nadir BG for each 
cat in each period of time. Consistent with previous 
reports, many cats showed a large variation in BG val-
ues, even when the BGCs were only separated by a few 
days.34 However, it may also indicate that the BGC inter-
vals were too defensive, resulting in suboptimal glycae-
mic control. In the studies by Roomp and Rand,15,28 the 
intensive BG monitoring may have led to a faster reduc-
tion of BG, which may have contributed to an increased 
rate of remission.15,28 A direct comparison is not possible 
because no BG values were presented in the above 
mentioned article.15
In accordance with previous studies, glycaemic con-
trol based on evaluation of BG levels did not represent 
the degree of control perceived by the owners.26 Likewise, 
in a study with 54 diabetic cats, only six were well con-
trolled based on BG levels, whereas 31 owners believed 
that their cat responded well to treatment.21
Only a few cases of clinical hypoglycaemia were iden-
tified in our study, and none required acute veterinary 
attention. This is comparable to the findings in the previ-
ous study with detemir, where 1/18 cats experienced 
mild hypoglycaemia.15 Studies with other types of insu-
lin have reported higher frequencies of clinical hypogly-
caemia wherein some required intravenous glucose 
infusion.25,35 Therefore, the safety of detemir appears to 
be high.
There are several limitations to this study. First and 
foremost the retrospective design. In some instances, 
the medical records were incomplete, and the infor-
mation gathered at each visit was not strictly stand-
ardised but depended on the preference of the 
responsible veterinarian. This could have affected our 
results in multiple ways; for example, by over-/under-
estimating the clinical symptoms or by concealment of 
lack of compliance. The number of included cases is 
low, which may reflect the fact that some owners 
choose euthanasia over treatment after diagnosis of 
DM; unfortunately, this could not be assessed owing 
to the design of our record system. The low number of 
cases may also reflect that most veterinary practices 
are confident in treating feline DM, which limits the 
amount of referrals to our hospital.
Several of the included cats had attended far fewer 
control visits than recommended at our facility, most 
often owing to the owners not adhering to the recom-
mended timing of control visits. Had the owners adhered 
to our protocol more stringently, we may have experi-
enced a higher rate of remission. However, we believe 
that this level of owner compliance is not uncommon 
and therefore feel that our results are a fair representa-
tion of the outcome that owners and veterinarians can 
expect, when dealing with clients in a general practice. 
Suboptimal owner compliance was also noted in the 
study by Roomp and Rand,15 where 43/61 cats were 
excluded, 15 of these because of lack of compliance.15 
There may be several reasons for the owners to have 
inadequate motivation. Based on our experiences, in 
some owners’ opinion the regular BGCs are too time-
consuming and the ear-pricking is considered stressful 
for both cats and owners. Furthermore, some owners 
have financial concerns and hence skip the regular vet-
erinary follow-up visits. It may also be that some owners 
fail to comprehend the possible benefits of regular moni-
toring, and that this must be further emphasised by the 
attending veterinarian.
Finally, it would have been interesting to compare the 
included cats with cats treated with other types of insu-
lin during the same period; unfortunately, this was not 
possible because insulin detemir is first-choice insulin at 
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our hospital and the number of cats being treated with 
other insulin types was extremely low.
Conclusions
For the diabetic cats in this study, treatment with 
detemir resulted in moderate or good control of clinical 
symptoms in 93% of cats; even in cats previously treated 
with other types of insulin. The safety of detemir was 
excellent. The overall remission rate in this study was 
quite low, compared with results from a study using a 
protocol for intensive BG monitoring. This has led us to 
suspect that the treatment and monitoring protocol 
proposed by the AAHA may be too defensive, and that 
further studies in this area are relevant.
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